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Background: Small cell cervical carcinoma (SCCC) is a rare, aggressive tumor with a poor prognosis. However,
information in relation to its treatment is scarce due to the limited numbers of patients. The aim of this study was
to establish whether platinum-based combination chemotherapy may by beneficial in this patient population.
Methods: We carried out a multicenter, retrospective study comprising of 72 Chinese patients with SCCC. The
patients were treated between 1995 and 2010 at Sun Yat-sen Memorial Hospital or the Cancer Center of Sun
Yat-Sen University, and at the First Affiliated Hospital of Shantou University Medical College, China.
Results: Of the 72 patients, 46/72 (63.9%) had Federation of Gynecology and Obstetrics (FIGO) stage Ia–Ib2 and
26/72 (36.1%) had stage IIa–IV disease. Surgery was performed in 63/72 (87.5%) patients, 61/72 (84.7%) patients
received chemoradiotherapy and 35/72 (48.6%) received radiotherapy. The 3-year overall survival (OS) and
disease-free survival (DFS) rates were as follows: Ia (100%, 100%); Ib1 (62%, 57%); Ib2 (53%, 48%); IIa (36%, 23%); IIb
(29%, 21%); IIIb (50%, 50%); and IV (0%, 0%), respectively. The estimated 3-year OS and DFS rates in patients who
received platinum-based combination chemotherapy (etoposide + cisplatin [EP], or paclitaxel + cisplatin [TP]) as part
of their adjuvant treatment were 64.8% and 63.0%, respectively, compared to 25.2% and 22.0% in those who did
not (P = 0.0003; P = 0.0003). Univariate analysis showed that platinum-based combination chemotherapy was
associated with improved survival compared to other chemotherapy techniques or no chemotherapy (OS: HR =
0.227; 95% CI, 0.099–0.524; P = 0.001; DFS: HR = 0.210; 95% CI, 0.087–0.506; P = 0.001). Multivariate analysis identified
FIGO stage, lymphatic metastasis and platinum-based combination chemotherapy as independent prognostic
factors for improved survival in patients with SCCC.
Conclusions: Platinum-based combination chemotherapy (with EP or TP) can improve the 3-year survival outcomes
in patients with SCCC. Therefore, it should be considered an important component in a future standardized
treatment strategy for SCCC.
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Table 1 Treatment modalities for patients with SCCC
according to FIGO stage
Treatment





Surgery alone 3 (6.5) 3 (11.5)
Surgery + adjuvant chemotherapy 27 (58.7) 3 (11.5)
Surgery + adjuvant radiotherapy 1 (2.2) 4 (15.4)
Surgery + adjuvant concurrent
chemoradiotherapy
13 (28.3) 9 (34.6)
Chemotherapy alone 1 (2.2) 0 (0)
Radiotherapy alone 0 (0) 4 (15.4)
Surgery + adjuvant concurrent
chemoradiotherapy
0 (0) 2 (7.7)
No treatment 1 (2.2) 1 (3.8)
FIGO, International Federation of Gynecology and Obstetrics.
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Small cell cervical carcinoma (SCCC) was first described
in 1957. It is a rare and aggressive cancer accounting for
less than 3% of all cervical neoplasms [1-8]. Previous re-
ports have shown that women diagnosed with SCCC
have a higher frequency of lymph node metastases, lym-
phovascular invasion and recurrence, and have a poorer
prognosis compared to women with other types of cer-
vical malignancies [9-11]. The 5-year survival rates vary
from 0% to 30% [12-14]. Moreover, SCCC is associated
with rapid, distant metastasis to sites including the lung,
liver, brain, bone, pancreas and lymph nodes, resulting
in treatment failure in most cases [15-19].
The aggressive nature of SCCC and low survival rates
mean that it is imperative to develop effective treat-
ments to improve the outcomes of patients with SCCC.
Due to its rarity, the time period required to enroll a
sufficient number of patients for analysis is long, and
an optimal, standardized treatment strategy for SCCC
remains to be established. Most clinicians favor the use
of platinum-based combination chemotherapy in the
treatment of patients with SCCC because of its similar-
ities to small cell lung cancer; however, its role in these
therapies has not been clearly defined. In this study, we
report a multicenter, retrospective trial comprising of
72 Chinese women diagnosed with SCCC, with the aim
of defining an optimal platinum-based combination




A total of 72 Chinese patients diagnosed with SCCC be-
tween January 1995 and January 2010 at the Cancer
Center of Sun Yat-sen University (50 patients), the Sun
Yat-sen Memorial Hospital of Sun Yat-Sen University
(12 patients) and the First Affiliated Hospital of the
Medical College of Shantou University (10 patients)
were enrolled in this study. The selection criteria were
as follows: confirmed histopathologic diagnosis of SCCC;
no previous history of malignancy or a secondary pri-
mary tumor; detailed clinicopathologic data and follow-
up data. Histologic classification of SCCC was per-
formed by light microscopy, according to the definitions
set by the World Health Organization (1981) for small
cell cancer lung. Immunohistochemical neuron-specific
enolase and silver staining had also been performed. The
identification of any small cell component was consid-
ered sufficient for the patient to be included. The cancer
was staged according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system. Clin-
ical information for each patient was obtained from med-
ical records. Disease status and vital data for each patient,
including tumor recurrence and patient death, wereobtained from a prospectively maintained hospital tumor
registry. All patients agreed to participate in the study and
gave written informed consent. This study was approved
by the medical ethics committee of Second Affiliated
Hospital of Nanchang University and Cancer Center of
Sun Yat-Sen University.Treatment
The initial treatments consisted of primary surgery with or
without neoadjuvant treatment, radiotherapy, or chemo-
therapy alone. With the exception of patients with surgical
contraindications, all patients diagnosed with FIGO stage
Ia–Ib2 SCCC underwent type II radical surgery, as de-
scribed by Piver et al. [20]. Patients with stage IIa–IV dis-
ease received radical surgery, palliative surgery of no
surgery (Table 1). Patients with high-risk factors underwent
type II radical surgery followed by postoperative adjuvant
therapy. All hysterectomy specimens were collected
and subjected to pathological analysis. Individualized
postoperative treatment consisted of radiotherapy, con-
current chemoradiotherapy or chemotherapy alone.
Radiotherapy consisted of external pelvic irradiation ad-
ministered using a multiportal technique, with a dose
of 1.8–2.0 Gy administered daily to a total dose of
50 Gy over 5–6 weeks. The paraortic region was irradiated
when metastases were detected in the common iliac or
paraortic nodes, with a dose of 45 Gy administered over
5 weeks. Chemoradiotherapy was scheduled as follows:
cisplatin (60 mg/m2) on day 1 and etoposide (100 mg/m2)
daily for 3 days every 3 weeks for 4 cycles. The first 2 cy-
cles of etoposide were given with concurrent radiotherapy
on days 1 and 22. The subsequent two cycles of etoposide
were given following radiotherapy. Chemotherapy alone
was administered in the form of cisplatin (60–75 mg/m2)






1 29 Ia Yes EP ×4 No CR NED (98 M)
2 52 IIa Yes / Yes / DOD (8 M)
3 27 Ib2 Yes TP ×4 Yes CR NED (42 M)
4 58 Ib1 Yes VAC ×4 Yes PR NED (23 M)
5 42 Ib2 Yes VAC ×1 + EP ×6 No PROG DOD (17 M)
6 39 Ib2 Yes CBP ×2 + TP ×4 No SD DOD (28 M)
7 54 IIIb Yes P ×1 No PROG DOD (25 M)
8 43 Ib1 Yes / No / NED (119 M)
9 36 Ib1 Yes CAP ×2 No PROG DOD (22 M)
10 47 Ib1 Yes CBP ×4 Yes CR NED (70 M)
11 46 Ib2 Yes ITP ×4 Yes SD DOD (34 M)
12 38 IIa Yes CBP ×4 Yes SD DOD (38 M)
13 58 IIa Yes / No / DOD (6 M)
14 48 IIb Yes / Yes / DOD (2 M)
15 24 Ib2 Yes IP ×1 Yes PROG DOD (5 M)
16 51 Ib1 Yes VAC ×2 + EP ×2 No PROG DOD (23 M)
17 65 IIa Yes VAC ×2 + EP ×1 Yes PROG DOD (23 M)
18 37 IIb No / Yes / DOD (6 M)
19 42 IIa Yes VAC ×2 + EP ×2 Yes PR DOD (33 M)
20 51 Ib2 Yes EP ×4 No CR NED (43 M)
21 36 Ib1 Yes TP ×4 Yes PR DOD (11 M)
22 48 Ib2 Yes VAC ×2 + EP ×2 No PR NED (32 M)
23 55 Ib1 Yes (IP + CP) ×5 No PROG DOD (28 M)
24 41 Ib1 Yes EP ×3 No PR NED (20 M)
25 32 IIb No / Yes / NED (63 M)
26 40 IIIb Yes TP ×5 Yes PR NED (64 M)
27 44 Ib1 Yes EP ×4 / CR NED (59 M)
28 34 Ib1 No VAC ×2 + EP ×2 No PR NED (22 M)
29 62 IIb Yes / / / NED (20 M)
30 41 Ib2 Yes EP ×4 Yes CR NED (17 M)
31 56 Ib1 Yes EP ×4 Yes CR NED (46 M)
32 66 IIa Yes EP ×4 No CR NED (12 M)
33 39 IIb No / Yes / DOD (12 M)
34 38 Ib1 Yes EP ×4 Yes SD DOD (18 M)
35 54 Ib1 Yes EP ×4 No PR NED (15 M)
36 39 Ib1 Yes EP ×4 Yes PR NED (13 M)
37 38 Ib1 Yes EP ×4 No CR NED (24 M)
38 51 IIa Yes EP ×4 No CR NED (25 M)
39 47 Ib1 Yes EP ×4 Yes PR NED (26 M)
40 28 IV No / / / DOD (1 M)
41 40 Ib2 No / / / NED (8 M)
42 48 Ib1 Yes EP ×4 No CR NED (21 M)
43 57 IIa Yes EP ×4 Yes CR NED (11 M)
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Table 2 Treatment plans and outcomes of the 72 cases of small cell cervical carcinoma (Continued)
44 29 Ib2 Yes / No CR NED (29 M)
45 38 IIa Yes EP ×4 Yes SD DOD (18 M)
46 59 Ib1 Yes EP ×4 No / NED (16 M)
47 61 Ib1 Yes EP ×4 No CR NED (24 M)
48 43 Ib2 Yes EP ×4 Yes CR NED (28 M)
49 40 Ib1 Yes EP ×4 No CR NED (13 M)
50 42 Ib1 Yes VAC ×4 No CR NED (74 M)
51 45 Ib1 Yes / No / DOD (19 M)
52 52 Ib2 Yes EP ×4 No CR NED (46 M)
53 26 Ib1 Yes EP ×4 / CR NED (32 M)
54 31 IIb No EP ×4 + VAC ×2 Yes PR DOD (17 M)
55 55 Ib1 Yes EP ×4 No CR NED (50 M)
56 50 Ib1 Yes EP ×5 Yes PR DOD (29 M)
57 44 Ib2 Yes EP ×4 No CR DOD (33 M)
58 54 Ib1 Yes / Yes / DOD (38 M)
59 43 IIa Yes / Yes / DOD (15 M)
60 40 Ib2 Yes TP ×4 No PR DOD (34 M)
61 36 IIa Yes / Yes / DOD (14 M)
62 46 Ib1 Yes EP ×4 No PR DOD (49 M)
63 48 IIb Yes EP ×4 Yes PR DOD (20 M)
64 31 Ib1 Yes EP ×4 / CR NED (10 M)
65 33 IIb No VAC ×2 + EP ×6 Yes PROG DOD (11 M)
66 67 IIa Yes EP ×4 Yes CR NED (18 M)
67 53 IIb No / Yes / DOD (6 M)
68 38 IIa Yes EP ×4 + VAC ×2 Yes PR DOD (34 M)
69 42 Ia Yes EP ×4 No PR NED (32 M)
70 66 IIb Yes / No / DOD (5 M)
71 45 Ib2 Yes EP ×4 Yes CR NED (15 M)
72 41 Ib1 Yes EP ×4 Yes CR NED (13 M)
PMCT, postoperative chemotherapy; PMRT, postoperative radiotherapy; CT, chemotherapy; EP, etoposide + cisplatin; VAC, vincristine + doxorubicin +
cyclophosphamide; TP, paclitaxel + cisplatin; CBP, cyclophosphamide + bleomycin + carboplatin/cisplatin; CBP, cyclophosphamide + adriamycin + carboplatin/
cisplatin; ITP, ifosfamide + pirarubicin + cisplatin; CR, complete response; PR, partial response; SD, stable disease; PROG, progressive disease; M, months; DOD, died
of disease; NED, no evidence of disease.
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mg/m2) over 3 hours on day 1, with cisplatin (60–75 mg/
m2) on days 1 and 2. In this study, etoposide + cisplatin is
defined as EP; paclitaxel + cisplatin is defined as TP. In
general, 3–5 courses of chemotherapy were administered
at 3-week intervals. The details of each patient’s treatment
plan are given in Table 2.Statistical analysis
Overall survival (OS) and disease-free survival (DFS)
were determined using Kaplan-Meier survival curves
and the log-rank test. The Cox proportional hazards
model was used to estimate the independent prognostic
factors for OS and DFS. All analyses were performedusing SPSS v.13.0 software (SPSS Inc.; Chicago, IL,
USA). P-values <0.05 were considered statistically sig-
nificant. The end points of all 72 patients were updated
in May 2012.
Results
Clinicopathologic features of the 72 SCCC cases
The median age of the 72 patients enrolled in this study
was 43 years (range: 24–66 years). Of these, 46 (63.9%)
had FIGO stage Ia–Ib2 disease and 26 (36.1%) had stage
IIa–IV disease. A mixed histologic pattern comprising of
SCCC with squamous cell carcinoma or adenocarcinoma
was diagnosed in 22 (30.6%) patients; the remaining 50
(69.4%) patients had a pure histologic type of SCCC.
The 3-year OS rates were as follows: Ia (100%); Ib1
Table 3 Univariate and multivariate Cox regression analysis of factors associated with overall survival (OS) and disease-free survival (DFS)
Clinical variable
Overall survival Disease free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age(years) 0.632 (0.318-1.255) 0.190 0.547 (0.276-1.085) 0.084
≥40 (n = 27, 37.5%)
<40 (n = 45, 62.5%)
Tumor homology 1.717 (0.846-3.485) 0.135 1.681 (0.832-3.396) 0.148
Mixed (n = 22, 30.6%)
Pure (n = 50, 69.4%)
FIGO stage 3.883 (1.936-7.790) <0.001 3.478 (1.493-9.664) 0.004 3.572 (1.780-7.164) <0.001 3.104 (1.377-7.978) 0.007
IIa–IV (n = 26, 36.1%)
Ia–Ib2 (n = 46, 63.9%)
Tumor size 2.057 (1.022-4.141) 0.043 2.320 (1.148-4.688) 0.019
>4 cm (n = 27, 37.5%)
≤4 cm (n = 45, 62.5%)
lymphatic metastasis 3.235 (1.642-8.139) 0.009 3.617 (1.441-11.326) 0.006 4.237 (1.792-6.524) 0.005 4.852 (1.613-8.794) 0.014
Positive (n = 42, 58.3%)
Negative (n = 30, 41.7%)
Vascular space invasion 1.923 (0.967-3.824) 0.062 1.529 (0.764-3.059) 0.231
Positive (n = 33, 45.8%)
Negative (n = 39, 54.2%)
Depth of stromal invasion 2.039 (0.908-4.577) 0.084 2.480 (0.1.107-5.559) 0.027
>2/3 (n = 33, 45.8%)
≤2/3 (n = 28, 38.9%)
Chemotherapy 0.227 (0.099-0.524) 0.001 0.264 (0.099-0.671) 0.003 0.223 (0.101-0.496) <0.001 0.221 (0.091-0.603) 0.006
EP or TP (n = 36, 50.0%)
Others (n = 36, 50.0%)
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(0%). The 3-year DFS rates were as follows: Ia (100%);
Ib1 (57%); Ib2 (48%0; IIa (23%); IIb (21%); IIIb (50%);
and IV (0%). These rates were similar to those reported
by Cohen et al. [21] based on an analysis of 52 patients
diagnosed with small cell neuroendocrine carcinoma
(SmCC) in Japan. They reported 4-year OS rates of Ib1
(63%); Ib2 (67%); IIb (30%); IIIb (29%); and IVb (25%),
and 4-year DFS rates of Ib1 (59%); Ib2 (68%); IIb (13%);
and IIIb (17%). The other clinicopathologic characteris-
tics of the patients in our study are summarized in
Table 3. Hematoxylin-eosin stained images of the speci-
mens revealed small, round tumor cells arranged in solid
sheets with scant cytoplasm, a high nuclear/cytoplasm
ratio and indistinct cell borders (Figure 1A). A high
proportion of mitotic cells were observed, and both squa-
mous cell carcinoma and adenocarcinoma components were
present, in addition to SCCC cells (Figure 1B). Vessel perme-
ation was also observed in some specimens (Figure 1C).
Many of the cases were positive for immunohistochem-
ical neuron-specific enolase staining (Figure 1D).
Relationship between different treatments and survival in
patients with SCCC
To determine whether platinum-based combination chemo-
therapy may be beneficial for the prognosis of patients withFigure 1 Hematoxylin-eosin (H&E) stained SCCC tissue specimens. (A)
arranged in solid sheets with a diffuse or trabecular pattern (magnification,
the cells and clusters of small cell carcinoma cells can be seen in the vesse
not infiltrate, beneath the squamous epithelium (magnification, ×100). (D)
positive cytoplasmic staining of the tumor cells (magnification, ×100).SCCC, the survival rates in patients who received adjuvant
chemotherapy (EP or TP) were compared to those who re-
ceived alternative adjuvant treatments. Our results re-
vealed that the estimated 3-year OS rates were 64.8%
vs. 25.2%, between these two groups, respectively (P =
0.0003; Figure 2A). The corresponding 3-year DFS rates
were 63.0% vs. 22.0%, respectively (P = 0.0001; Figure 2B).
Of the 72 patients enrolled in this study, 63 (87.5%) had
undergone radical hysterectomy as the main mode of
treatment. The treatment modalities for each patient are
summarized in Table 2. We also assessed whether multi-
modal therapy improved prognosis. Due to the limited
number of patients, we divided them into the following
four groups: those who received adjuvant chemotherapy
(n = 31), those who received adjuvant radiotherapy (n = 10),
those who received adjuvant chemoradiotherapy (n = 18),
and those who received no adjuvant therapy (n = 13).
Patients who received adjuvant chemotherapy tended
to have improved survival, with a 3-year OS rate of
54.5% compared to 0% in those who received adjuvant
radiotherapy, 41.1% in those who received adjuvant
chemoradiotherapy, and 43.8% in those who received
no adjuvant therapy. Contrary to our expectations,
patients who received adjuvant radiotherapy tended
to have a poorer prognosis than those who received
no radiation (Figure 2C,D). Based on these results,Small, round tumor cells with a high nuclear/cytoplasmic ratio are
×40). (B) Adenocarcinomatous components are present in some of
ls (magnification, ×40). (C) Small cell carcinoma cells pervade, but do
Immunohistochemical staining for neuron-specific enolase shows




























































































Figure 2 Kaplan-Meier curves of overall survival (OS) and disease-free survival (DFS) for different treatment strategies in SCCC. (A and
B): Comparisons between survival rates in patients who received adjuvant chemotherapy (etoposide + cisplatin [EP]; or paclitaxel + cisplatin [TP])
as part of their adjuvant treatment, compared to those who received alternative adjuvant therapies. (C and D) Comparisons between the survival
rates in patients who received adjuvant chemotherapy (CT), adjuvant radiotherapy (RT), adjuvant chemoradiotherapy (CT + RT), or no adjuvant
therapy (NO).
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recommended in the adjuvant treatment of patients
with SCCC.
Univariate and multivariate analyses to determine the
prognostic factors in SCCC
To identify the prognostic factors for survival in patients
with SCCC, we performed univariate and multivariate
analyses of OS and DFS rates using the Cox proportional
hazard model. Univariate analyses showed that FIGO
stage (P < 0.001), lymphatic metastasis (P = 0.006), and EP
or TP platinum-based combination chemotherapy (P =
0.001) were associated with the prognosis of patients with
SCCC. Although vascular space invasion and depth of
stromal invasion indicated poor survival, the effects were
not statistically significant. In contrast, age, tumor size
and tumor homology were not associated with prognosis
in SCCC (P > 0.05).
After adjusting for potential confounding factors, multi-
variate analyses identified FIGO stage (HR, 3.478; 95% CI,
1.493–9.664; P = 0.004), lymphatic metastasis (HR, 3.617;
95% CI, 1.441–11.326; P = 0.006), and EP or TP platinum-based combination chemotherapy (HR, 0.264; 95% CI,
0.099–0.671; P = 0.003) as significant independent prog-
nostic factors for overall survival in SCC (Table 2).Discussion
SCCC is a rare malignancy. Consequently, prospective ran-
domized trials to assess the impact of various treatments
on patient outcome have not been possible. Attempts by
the Gynecologic Oncology Group to study SCCC have
failed due to insufficient patient numbers. In recent years,
novel methods for the treatment of SCCC have attempted
to replicate successful treatments for small cell lung carcin-
oma. The management of SCCC has also been influenced
by the success of concurrent chemoradiotherapies in other
types of locally advanced cervical cancer. Despite these ap-
proaches, an optimal treatment strategy for SCCC remains
to be established. In this study, we carried out a retrospect-
ive, multicenter trial consisting of 72 Chinese patients with
SCCC in order to determine the most effective platinum-
based combination chemotherapeutic strategy to improve
survival outcome in these patients.
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patients with stage I–II small cell lung carcinoma [22],
and its role in stage III disease is considered investiga-
tional [23,24]. In contrast, there have been few studies on
the role of surgery in the treatment of SCCC, and it is un-
clear which patients, if any, should undergo radical hyster-
ectomy as opposed to primary treatment with combined
chemotherapy and radiotherapy. However, most gyneco-
logic oncologists and patients in China favor radical hys-
terectomy. The majority of patients with SCCC enrolled
in this study (87.5%) had undergone radical hysterectomy
as the main mode of treatment. Although several reports
have suggested that radical hysterectomy does not prolong
patient survival in SCCC [25], our results have indicated
that it was an important component in the multimodal
treatment of SCCC. In our centers, the standard approach
to treating patients with SCCC is radical hysterectomy
followed by several cycles of platinum-based combination
chemotherapy.
Platinum-based combination chemotherapy has been
reported to be as beneficial in patients with SCCC as it
is for patients with lung cancer [26]. However, SCCC
differs from small cell lung cancer due to its lower risk
of brain metastasis and this benefit remains to be con-
firmed. Several case studies and small-series reports have
indicated that platinum-based combination chemother-
apy may have positive outcomes in patients with SCCC:
Hoskins et al. reported a 3-year failure-free rate of 80%
in 31 patients with early stage disease (stage I–II) who
underwent combination therapies that included etopo-
side and cisplatin [25]; Gardner et al. reported that eto-
poside/platinum-based chemotherapy was effective for
neuroendocrine carcinomas of the gynecologic tract but
not for well-differentiated carcinoid tumors [27]; and
Chang et al. found that chemotherapies containing a
combination of cisplatin and etoposide could be effective
in patients with early stage SCCC following radical hys-
terectomy [18]. Although comparisons between series
can be problematic due to selection bias and different
treatment modalities, our data supports the role of
platinum-based combination chemotherapy in the treat-
ment of patients with SCCC. Patients who received
chemotherapy (with EP or TP) as part of their adjuvant
treatment had estimated 3-year OS and DFS rates of
64.8% and 63.0%, respectively, compared to 25.2% and
22.0%, respectively, in those who received alternative ad-
juvant therapies (P < 0.05).
Several studies have reported that disease stage was the
strongest predictor of outcome, and that other factors, in-
cluding age, tumor size, depth of stromal invasion, vascu-
lar space invasion, were also prognostic factors in SCCC
[28,29]. However, our univariate and multivariate analyses
found no association between age, depth of stromal inva-
sion or vascular space invasion with patient outcome inSCCC. In contrast, we found that FIGO stage, lymphatic
metastasis and platinum-based combination chemother-
apy were independent prognostic factors for improved
survival in SCCC. To our knowledge, this is the first re-
port to reveal that platinum-based combination chemo-
therapy is an independent prognostic factor for patients
with SCCC.
Conclusions
Our study has demonstrated that improved survival out-
comes can be achieved in patients with SCCC by incorp-
orating platinum-based combination chemotherapy into
adjuvant treatment strategies. Although this study was
retrospective in design, it is one of the largest series re-
ported to date, and the results could be an important con-
tribution to our understanding and future therapies of this
rare and aggressive tumor.
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